Alarm As Novartis Exits Antibiotics Space

The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."

Book keeper
Antibiotic R&D costs do not add up for Novartis • Source: Shutterstock

Novartis AG is the latest big pharma to exit the antibiotics arena, deciding to ditch its antibacterial and antiviral research programs and spend its resources in other areas.

The Swiss major confirmed the decision in an email to Scrip saying that workers at its Emeryville, California facilities have...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category